Developer docs
API playgroundTry for free, no card

Search company profiles

Immuron

Full company profile

uuid0002mkn

Namestring
Immuron
Legal namestring
Immuron Limited
Websiteurl
immuron.com
Company typeenum
Public
Founded yearint
1994
Descriptiontext

Immuron Limited is a commercial and clinical stage Australian biopharmaceutical company that develops and commercializes orally delivered polyclonal antibodies derived from a proprietary hyper-immune bovine colostrum platform. Cows are immunized with pathogen-specific vaccines before calving, and the first post-partum milking colostrum is harvested to produce IgG antibodies that resist stomach acid and digestive enzymes, allowing targeted action against enteric pathogens within the gastrointestinal tract without entering the bloodstream. The company is listed on the ASX (IMC) since 1999 and on NASDAQ (IMRN) since 2017, headquartered in Blackburn North, Victoria, with a registered office in Carlton.

The commercial portfolio centers on Travelan, an over-the-counter immune supplement listed on the Australian Register of Therapeutic Goods (AUST L 106709) for reducing the risk of travelers' diarrhea, and ProIBS, a clinically proven IBS symptom relief product (Aust L 482225) containing the proprietary AVH200 Aloe Vera extract launched in Australia in December 2025; the legacy Protectyn product has been discontinued in favor of Travelan. The clinical pipeline includes IMM-529, which received FDA IND approval in November 2025 for a Phase 2 trial in Clostridioides difficile infection targeting a projected US$400 million annual revenue opportunity, and IMM-124E (the Travelan active ingredient) with positive Phase 2 interim results supporting an end-of-Phase 2 meeting with the FDA. Research collaborations span the U.S. Department of Defense (US$3.5 million research agreement, August 2024), Naval Medical Research Command, Walter Reed Army Institute of Research, CSIRO, Monash University, University of Melbourne, Tréidlia Biovet, NIH, and Uniformed Services University.

The business model combines direct-to-consumer e-commerce (immuron.com.au and Amazon), retail pharmacy distribution in Australia and Canada (Jean Coutu), and government/non-dilutive research funding. FY26 global sales reached A$7.7 million (up 6% year-over-year) following a 49% YoY jump to A$7.29 million in FY25, with Australia contributing A$5.8 million and the USA US$1.2 million. Pricing ranges from A$19.99 to A$43.95 per pack in AUD, and the company remains unprofitable with H1 FY26 net loss of A$1.92 million (improved from A$2.49 million in the prior year) and an A$10 million cash position following a A$7.3 million ATM facility raise in 2025.

Short descriptiontext

Immuron Limited is a commercial-stage Australian biopharmaceutical company developing orally delivered polyclonal antibodies from hyper-immune bovine colostrum to treat gastrointestinal diseases. It markets Travelan for travelers' diarrhea and ProIBS for IBS, and is developing IMM-529 for C. difficile infection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral polyclonal antibodies, bovine colostrum therapeutics, travelers diarrhea prevention, IBS symptom relief, gastrointestinal biopharmaceuticals
Industry1 code
PRIMARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Food (Health) Supplement Retailers456191
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oral Polyclonal Antibody Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Commercial Product Sales
TypeOne Time License
Description

Revenue from direct sales of commercial products including Travelan (travelers' diarrhea prevention), ProIBS (IBS symptom relief), and Protectyn (gut and liver health). Products sold through e-commerce, pharmacies, and retail stores in Australia, USA, and Canada.

immuron.com.au
2Government Research Funding
TypeLicensing Royalties
Description

Research agreement funding from U.S. Department of Defense (approximately $3.5 million) for development of improved Travelan formulation targeting enteric bacteria like Campylobacter, Shigella, and E. coli for military protection.

stocktitan.net
3Clinical Development Partnerships
TypeLicensing Royalties
Description

Strategic partnerships with U.S. Department of Defense, Naval Medical Research Command, and Walter Reed Army Institute of Research for co-development of hyper-immune therapeutics targeting military-relevant pathogens.

newswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Travelan 30-caplet pack for travelers' diarrhea prevention
ModelUnit PricingBilling cadencePay-as-you-go
Notes

A$43.95 per 30-caplet pack. Take one caplet before every meal for protection.

immuron.com.au
2ProIBS 10-sachet pack for IBS symptom relief
ModelUnit PricingBilling cadencePay-as-you-go
Notes

A$19.99 per 10 sachets. Adults and children 13+ take 1-2 sachets daily.

immuron.com.au
3ProIBS 30-sachet pack for IBS symptom relief
ModelUnit PricingBilling cadencePay-as-you-go
Notes

A$42.99 per 30 sachets. Bulk savings compared to 10-pack.

immuron.com.au
4Protectyn 30-pack for gut and liver health
ModelUnit PricingBilling cadencePay-as-you-go
Notes

A$39.95 per 30-pack. Same formulation as Travelan.

immuron.com.au
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Travelan
Description

Over-the-counter immune supplement for reducing the risk of travellers' diarrhoea caused by enterotoxigenic E. coli. Contains hyperimmune bovine colostrum powder as active ingredient.

immuron.com.au
+4 more records
Core offering1 text field

Immuron develops and commercializes orally delivered polyclonal antibody products derived from a proprietary hyper-immune bovine colostrum platform. The company markets Travelan®, an over-the-counter immune supplement for reducing the risk of travelers' diarrhea, and ProIBS®, a clinically proven medicine for relief of irritable bowel syndrome symptoms. Its clinical pipeline includes IMM-529 (FDA IND-approved Phase 2 candidate for C. difficile infection) and IMM-124E, the active pharmaceutical ingredient in Travelan being developed for expanded enteric pathogen protection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 90% efficacy in preventing travelers' diarrhea in clinical trials
+4 more records
Product overview1 text field

Immuron is a commercial and clinical stage Australian biopharmaceutical company with a proprietary technology platform based on hyperimmune bovine colostrum producing orally delivered polyclonal antibodies. The company markets two consumer health products: Travelan® (OTC immune supplement for travellers' diarrhoea, AUST L 106709) and ProIBS® (clinically proven IBS symptom relief, Aust L 482225). Protectyn® (AUST L 231001) is discontinued and replaced by Travelan®. The clinical pipeline includes IMM-529 (Phase 2 ready for C. difficile infection after FDA IND approval) and IMM-124E (the active ingredient in Travelan® being developed for expanded travellers' diarrhoea protection). The platform technology enables oral antibody delivery within the gastrointestinal tract without entering the bloodstream.

Product and service2 records
1Travelan®
CategoryTravelers' Diarrhea Prevention
Description

Over-the-counter immune supplement that reduces the risk of travelers' diarrhea and minor gastrointestinal disorders. Contains hyperimmune bovine colostrum powder with polyclonal antibodies that bind to Enterotoxigenic E. coli, preventing attachment to intestinal walls. Sold in Australia, Canada, and the US for travelers visiting high-risk destinations.

2ProIBS®
CategoryIBS Symptom Relief
Description

Clinically proven medicine for relief of symptoms related to medically diagnosed irritable bowel syndrome (IBS) in adults and children 13+. Contains AVH200® proprietary Aloe Vera extract that forms a protective hydrogel film in the gut while binding harmful bacteria. Available in 10-pack and 30-pack sachets with citrus flavor, listed on Australian Register of Therapeutic Goods (Aust L 482225).

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Naval Medical Research Command (NMRC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-16
Description

Collaboration with NMRC on research targeting Enterotoxigenic E. coli and Campylobacter for U.S. military diarrheal disease prevention. Part of long-term relationship with Department of Defense Infectious Diseases Research Directorate.

globenewswire.com
2Walter Reed Army Institute of Research (WRAIR)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-16
Description

Joint research with WRAIR focusing on Shigella strains not present in current Travelan formulation. WRAIR conducted comprehensive study testing Travelan against 180 bacteria samples with 100% reactivity.

globenewswire.com
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Quebec pharmacy chain distribution partnership for Travelan sales in Canada. Initial sales began in Q3 FY2026 with 82% quarter-over-quarter growth in Canadian sales.

4CSIRO
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with CSIRO's Microbial Manufacturing Facility for development of improved scalable manufacturing process for antigenic material required for Travelan production. Work includes pilot-scale production and purification.

immuron.com.au
5Monash University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ARC linkage research agreement for C. difficile research project since 2011. Research focused on developing technology for IMM-529 evaluation in humans. Also examining therapeutic efficacy of antibodies targeting Uropathogenic E. coli.

immuron.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing partnership leading to commercialization of Travelan. University provided 'gold standard' animal testing models for influenza research with exclusive commercialization rights.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing partnership dating back to 2003 for manufacture of ETEC vaccines. Tréidlia specializes in quality veterinary vaccines and diagnostic laboratory services.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Engaged CVD for comprehensive analytical support for clinical development programs with FDA (SAH and NASH). CVD has international reputation for vaccine development against enteric diseases.

9Pharmaron CPC
Strategic tierMajorTypeStrategic or Co-development Partner
Description

FDA inspected Clinical Research Facility (Inpatient Unit) in Baltimore, Maryland conducting Phase 2 clinical trial for Travelan using controlled human infection model (CHIM). Clinicaltrials.gov identifier: NCT05933525.

stocktitan.net
Strategic tierMajorTypeStrategic or Co-development Partner
Description

P2TD study evaluating IMM-124E (Travelan active ingredient) for gut health during deployment. Results delayed to end of November 2025 due to U.S. government shutdown; will inform dosing strategy at FDA end-of-Phase 2 meeting.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage microbiome therapeutics company developing treatments for recurrent C. difficile infection; emerging player with overlapping target indication and regulatory pathway to IMM-529.

TypeEmerging player
Description

Microbiome therapeutics subsidiary of Ferring developing Rebyota for recurrent C. difficile infection; comparable therapeutic approach and CDI focus to IMM-529.

TypeBroad incumbent
Description

Global biopharmaceutical company with a major gastroenterology franchise (Humira, Skyrizi, Rinvoq, Linzess) targeting IBD/IBS; broad incumbent in the gastroenterology space where Immuron is positioning IMM-529 and ProIBS.

TypeDirect peer
Description

Japanese probiotics consumer health company with global distribution of Lactobacillus-based gut health products; comparable consumer supplement model and gut health indication overlap with ProIBS.

TypeBroad incumbent
Description

Global consumer health and vaccines company with Imodium (loperamide) for diarrhea and travel vaccines; overlaps with both Travelan's OTC traveler diarrhea positioning and the broader traveler's diarrhea treatment market.

TypeDirect peer
Description

Global bioscience company with a leading probiotics and microbial cultures business serving food, dietary supplement, and pharma customers; comparable consumer health positioning and gut health indication overlap with ProIBS.

TypeBroad incumbent
Description

Specialty gastroenterology business within Bausch Health with established prescription products for CDI and IBS-related conditions; comparable target indications and physician-channel go-to-market.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing treatments for recurrent C. difficile infection (VOWST/SER-109), directly comparable to Immuron's IMM-529 in target indication, patient population, and regulatory pathway.

TypeBroad incumbent
Description

Global specialty gastroenterology and reproductive health company with established CDI treatment (Rebyota, acquired via Rebiotix) and broad gut health portfolio; overlaps with Immuron's IMM-529 and Travelan/ProIBS targets.

10BioGaia
TypeDirect peer
Description

Swedish probiotics company selling clinically validated gut-health consumer supplements globally, directly comparable to Immuron's ProIBS and Protectyn/Travelan consumer health positioning and pharmacy/retail distribution model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immuron

Oral Polyclonal Antibody Therapeuticsimmuron.com

Immuron Limited is a commercial-stage Australian biopharmaceutical company developing orally delivered polyclonal antibodies from hyper-immune bovine colostrum to treat gastrointestinal diseases. It markets Travelan for travelers' diarrhea and ProIBS for IBS, and is developing IMM-529 for C. difficile infection.

What Immuron does

Immuron Limited is a commercial and clinical stage Australian biopharmaceutical company that develops and commercializes orally delivered polyclonal antibodies derived from a proprietary hyper-immune bovine colostrum platform. Cows are immunized with pathogen-specific vaccines before calving, and the first post-partum milking colostrum is harvested to produce IgG antibodies that resist stomach acid and digestive enzymes, allowing targeted action against enteric pathogens within the gastrointestinal tract without entering the bloodstream. The company is listed on the ASX (IMC) since 1999 and on NASDAQ (IMRN) since 2017, headquartered in Blackburn North, Victoria, with a registered office in Carlton.

The commercial portfolio centers on Travelan, an over-the-counter immune supplement listed on the Australian Register of Therapeutic Goods (AUST L 106709) for reducing the risk of travelers' diarrhea, and ProIBS, a clinically proven IBS symptom relief product (Aust L 482225) containing the proprietary AVH200 Aloe Vera extract launched in Australia in December 2025; the legacy Protectyn product has been discontinued in favor of Travelan. The clinical pipeline includes IMM-529, which received FDA IND approval in November 2025 for a Phase 2 trial in Clostridioides difficile infection targeting a projected US$400 million annual revenue opportunity, and IMM-124E (the Travelan active ingredient) with positive Phase 2 interim results supporting an end-of-Phase 2 meeting with the FDA. Research collaborations span the U.S. Department of Defense (US$3.5 million research agreement, August 2024), Naval Medical Research Command, Walter Reed Army Institute of Research, CSIRO, Monash University, University of Melbourne, Tréidlia Biovet, NIH, and Uniformed Services University.

The business model combines direct-to-consumer e-commerce (immuron.com.au and Amazon), retail pharmacy distribution in Australia and Canada (Jean Coutu), and government/non-dilutive research funding. FY26 global sales reached A$7.7 million (up 6% year-over-year) following a 49% YoY jump to A$7.29 million in FY25, with Australia contributing A$5.8 million and the USA US$1.2 million. Pricing ranges from A$19.99 to A$43.95 per pack in AUD, and the company remains unprofitable with H1 FY26 net loss of A$1.92 million (improved from A$2.49 million in the prior year) and an A$10 million cash position following a A$7.3 million ATM facility raise in 2025.

Immuron firmographics

Firmographics
Name
Immuron
Legal name
Immuron Limited
Website
https://immuron.com
Company type
Public
Founded year
1994
Operating status
Operating
Headcount range
11–50 employees
Short description
Immuron Limited is a commercial-stage Australian biopharmaceutical company developing orally delivered polyclonal antibodies from hyper-immune bovine colostrum to treat gastrointestinal diseases. It markets Travelan for travelers' diarrhea and ProIBS for IBS, and is developing IMM-529 for C. difficile infection.
Ownership category
akta.pro rank

Immuron industry classification

Industry
Product category
Oral Polyclonal Antibody Therapeutics
NAICS
Food (Health) Supplement Retailers (456191)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Oral polyclonal antibodies
  • Bovine colostrum therapeutics
  • Travelers diarrhea prevention
  • IBS symptom relief
  • Gastrointestinal biopharmaceuticals

Where Immuron is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Immuron business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Commercial Product Sales: Revenue from direct sales of commercial products including Travelan (travelers' diarrhea prevention), ProIBS (IBS symptom relief), and Protectyn (gut and liver health). Products sold through e-commerce, pharmacies, and retail stores in Australia, USA, and Canada.
  2. Government Research Funding: Research agreement funding from U.S. Department of Defense (approximately $3.5 million) for development of improved Travelan formulation targeting enteric bacteria like Campylobacter, Shigella, and E. coli for military protection.
  3. Clinical Development Partnerships: Strategic partnerships with U.S. Department of Defense, Naval Medical Research Command, and Walter Reed Army Institute of Research for co-development of hyper-immune therapeutics targeting military-relevant pathogens.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTravelan 30-caplet pack for travelers' diarrhea prevention
Unit PricingPay-as-you-goProIBS 10-sachet pack for IBS symptom relief
Unit PricingPay-as-you-goProIBS 30-sachet pack for IBS symptom relief
Unit PricingPay-as-you-goProtectyn 30-pack for gut and liver health

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Immuron product offering

Product offering

Core offering

Immuron develops and commercializes orally delivered polyclonal antibody products derived from a proprietary hyper-immune bovine colostrum platform. The company markets Travelan®, an over-the-counter immune supplement for reducing the risk of travelers' diarrhea, and ProIBS®, a clinically proven medicine for relief of irritable bowel syndrome symptoms. Its clinical pipeline includes IMM-529 (FDA IND-approved Phase 2 candidate for C. difficile infection) and IMM-124E, the active pharmaceutical ingredient in Travelan being developed for expanded enteric pathogen protection.

Product overview

Immuron is a commercial and clinical stage Australian biopharmaceutical company with a proprietary technology platform based on hyperimmune bovine colostrum producing orally delivered polyclonal antibodies. The company markets two consumer health products: Travelan® (OTC immune supplement for travellers' diarrhoea, AUST L 106709) and ProIBS® (clinically proven IBS symptom relief, Aust L 482225). Protectyn® (AUST L 231001) is discontinued and replaced by Travelan®. The clinical pipeline includes IMM-529 (Phase 2 ready for C. difficile infection after FDA IND approval) and IMM-124E (the active ingredient in Travelan® being developed for expanded travellers' diarrhoea protection). The platform technology enables oral antibody delivery within the gastrointestinal tract without entering the bloodstream.

Differentiator

Problem solved

Functional benefit

Brands

  • Travelan: Over-the-counter immune supplement for reducing the risk of travellers' diarrhoea caused by enterotoxigenic E. coli. Contains hyperimmune bovine colostrum powder as active ingredient.
  • Protectyn
  • ProIBS
  • IMM-529
  • IMM-124E

Products and services

  • Travelan® Over-the-counter immune supplement that reduces the risk of travelers' diarrhea and minor gastrointestinal disorders. Contains hyperimmune bovine colostrum powder with polyclonal antibodies that bind to Enterotoxigenic E. coli, preventing attachment to intestinal walls. Sold in Australia, Canada, and the US for travelers visiting high-risk destinations.
  • ProIBS® Clinically proven medicine for relief of symptoms related to medically diagnosed irritable bowel syndrome (IBS) in adults and children 13+. Contains AVH200® proprietary Aloe Vera extract that forms a protective hydrogel film in the gut while binding harmful bacteria. Available in 10-pack and 30-pack sachets with citrus flavor, listed on Australian Register of Therapeutic Goods (Aust L 482225).

Quantifiable outcome

  • Up to 90% efficacy in preventing travelers' diarrhea in clinical trials
  • +4 more outcomes

Companies that use Immuron

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Immuron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Immuron partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and major.

  • Naval Medical Research Command (NMRC)coreStrategic or Co-development Partner · 16 August 2024Collaboration with NMRC on research targeting Enterotoxigenic E. coli and Campylobacter for U.S. military diarrheal disease prevention. Part of long-term relationship with Department of Defense Infectious Diseases Research Directorate.
  • Walter Reed Army Institute of Research (WRAIR)coreStrategic or Co-development Partner · 16 August 2024Joint research with WRAIR focusing on Shigella strains not present in current Travelan formulation. WRAIR conducted comprehensive study testing Travelan against 180 bacteria samples with 100% reactivity.
  • Jean Coutu Pharmacy GroupmajorChannel Partner/ Reseller/ DistributorQuebec pharmacy chain distribution partnership for Travelan sales in Canada. Initial sales began in Q3 FY2026 with 82% quarter-over-quarter growth in Canadian sales.
  • CSIROcoreStrategic or Co-development PartnerCollaboration with CSIRO's Microbial Manufacturing Facility for development of improved scalable manufacturing process for antigenic material required for Travelan production. Work includes pilot-scale production and purification.
  • Monash UniversitycoreStrategic or Co-development PartnerARC linkage research agreement for C. difficile research project since 2011. Research focused on developing technology for IMM-529 evaluation in humans. Also examining therapeutic efficacy of antibodies targeting Uropathogenic E. coli.
  • University of MelbournecoreStrategic or Co-development PartnerLong-standing partnership leading to commercialization of Travelan. University provided 'gold standard' animal testing models for influenza research with exclusive commercialization rights.
  • Tréidlia BiovetcoreStrategic or Co-development PartnerLong-standing partnership dating back to 2003 for manufacture of ETEC vaccines. Tréidlia specializes in quality veterinary vaccines and diagnostic laboratory services.
  • Center for Vaccine Development (CVD)majorStrategic or Co-development PartnerEngaged CVD for comprehensive analytical support for clinical development programs with FDA (SAH and NASH). CVD has international reputation for vaccine development against enteric diseases.
  • Pharmaron CPCmajorStrategic or Co-development PartnerFDA inspected Clinical Research Facility (Inpatient Unit) in Baltimore, Maryland conducting Phase 2 clinical trial for Travelan using controlled human infection model (CHIM). Clinicaltrials.gov identifier: NCT05933525.
  • Uniformed Services UniversitymajorStrategic or Co-development PartnerP2TD study evaluating IMM-124E (Travelan active ingredient) for gut health during deployment. Results delayed to end of November 2025 due to U.S. government shutdown; will inform dosing strategy at FDA end-of-Phase 2 meeting.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Immuron competitors and assessment

Company assessment

Emerging players

  • Finch Therapeutics: Clinical-stage microbiome therapeutics company developing treatments for recurrent C. difficile infection; emerging player with overlapping target indication and regulatory pathway to IMM-529.
  • Rebiotix (Ferring): Microbiome therapeutics subsidiary of Ferring developing Rebyota for recurrent C. difficile infection; comparable therapeutic approach and CDI focus to IMM-529.

Broad incumbents

  • AbbVie: Global biopharmaceutical company with a major gastroenterology franchise (Humira, Skyrizi, Rinvoq, Linzess) targeting IBD/IBS; broad incumbent in the gastroenterology space where Immuron is positioning IMM-529 and ProIBS.
  • GSK: Global consumer health and vaccines company with Imodium (loperamide) for diarrhea and travel vaccines; overlaps with both Travelan's OTC traveler diarrhea positioning and the broader traveler's diarrhea treatment market.
  • Bausch Health (Salix Pharmaceuticals): Specialty gastroenterology business within Bausch Health with established prescription products for CDI and IBS-related conditions; comparable target indications and physician-channel go-to-market.
  • Ferring Pharmaceuticals: Global specialty gastroenterology and reproductive health company with established CDI treatment (Rebyota, acquired via Rebiotix) and broad gut health portfolio; overlaps with Immuron's IMM-529 and Travelan/ProIBS targets.

Direct peers

  • Yakult Honsha: Japanese probiotics consumer health company with global distribution of Lactobacillus-based gut health products; comparable consumer supplement model and gut health indication overlap with ProIBS.
  • Chr. Hansen: Global bioscience company with a leading probiotics and microbial cultures business serving food, dietary supplement, and pharma customers; comparable consumer health positioning and gut health indication overlap with ProIBS.
  • Seres Therapeutics: Clinical-stage microbiome therapeutics company developing treatments for recurrent C. difficile infection (VOWST/SER-109), directly comparable to Immuron's IMM-529 in target indication, patient population, and regulatory pathway.
  • BioGaia: Swedish probiotics company selling clinically validated gut-health consumer supplements globally, directly comparable to Immuron's ProIBS and Protectyn/Travelan consumer health positioning and pharmacy/retail distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Immuron social profiles

Digital presence

Immuron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immuron leadership team

Management profile

Number of profiles

Profiles10 records

Immuron funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immuron M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immuron

What does Immuron do?

Immuron develops and commercializes orally delivered polyclonal antibody products derived from a proprietary hyper-immune bovine colostrum platform. The company markets Travelan®, an over-the-counter immune supplement for reducing the risk of travelers' diarrhea, and ProIBS®, a clinically proven medicine for relief of irritable bowel syndrome symptoms. Its clinical pipeline includes IMM-529 (FDA IND-approved Phase 2 candidate for C. difficile infection) and IMM-124E, the active pharmaceutical ingredient in Travelan being developed for expanded enteric pathogen protection.

Is Immuron a public or private company?

Immuron is a public company. It is classified as public and is currently operating.

When was Immuron founded?

Immuron was founded in 1994. It employs 11 to 50 people.

Where is Immuron based?

Immuron is headquartered in Melbourne, Australia, in the Oceania region.

How does Immuron make money?

Three revenue lines are on record. Commercial Product Sales are the primary driver. The others are government Research Funding and clinical Development Partnerships.

Who are Immuron's main competitors?

Emerging players on record are Finch Therapeutics and Rebiotix (Ferring). Broad incumbents are AbbVie, GSK, Bausch Health (Salix Pharmaceuticals) and Ferring Pharmaceuticals. Direct peers are Yakult Honsha, Chr. Hansen, Seres Therapeutics and BioGaia.

Does Immuron have an API?

No public API is recorded for Immuron.

What industry is Immuron in?

Immuron's product category is Oral Polyclonal Antibody Therapeutics. Its primary akta.pro industry code is HLAAAEAH, Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins). Its NAICS code is 456191 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingImmuron CEO Steven Lydeamore Presents at Emerging Growth ConferenceImmuron CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026, from 4:25-4:55 p.m. U.S. Eastern Time. The presentation is scheduled for that time slot.Ticker ReportImmuron (NASDAQ:IMRN) Stock Short Interest Report for SeptemberShort interest in Immuron fell 46.6% to 61,753 shares as of September 30th, with 0.8% of shares short sold. Analysts maintain a sell consensus, and the stock traded at $0.98 on Friday. The company reported a quarterly loss of $0.08 per share on revenue of $1.27 million.Quiver QuantitativeImmuron Limited Reports Nature Scientific Reports Publication of Phase 2 Travelan Study Showing Reduced ETEC-Related Adverse Events | IMRN Stock NewsImmuron published Phase 2 trial data for Travelan in Scientific Reports, showing a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo. The study did not meet primary efficacy endpoints due to a lower-than-expected placebo attack rate, but efficacy trends favored Travelan across multiple endpoints.The future of tradingImmuron says Phase 2 Travelan trial results published in Scientific ReportsImmuron published Phase 2 results for once-daily oral Travelan in Scientific Reports, which missed primary efficacy targets due to a low placebo illness rate. Secondary measures favored Travelan, showing fewer and less severe diarrheal illness, with a clean safety profile. Development now focuses on a delayed-release capsule for larger studies.Stock TitanImmuron Travelan Phase 2: 50% Fewer Adverse EventsImmuron published Phase 2 trial data for Travelan, showing a statistically significant 50% reduction in ETEC challenge-related adverse events versus placebo (P=0.0001). The study did not meet primary efficacy endpoints due to a lower-than-anticipated placebo attack rate (33% vs 70%), but efficacy trends favored Travelan. Immuron is advancing a once-daily delayed-release formulation for broader bacterial diarrheal disease prevention.Ticker ReportImmuron (NASDAQ:IMRN) Sees Significant Increase in Short InterestImmuron saw short interest surge 240.2% to 115,685 shares as of September 15th, with 1.5% of shares sold short. Analysts have a consensus "Sell" rating, and the stock traded down 2.5% to $1.16. The company reported a quarterly loss of $0.08 per share on $1.27 million revenue.AInvestWhy Is IMRN Stock Rising Today? Immuron Shares Surge After FY26 Sales Beat and FDA ClearanceImmuron shares surged 61.27% after reporting FY26 sales of A$7.7 million, up 6% from the prior year, and cash reserves of A$9 million. The company also received FDA clearance for its C. difficile treatment IMM-529 and signed a U.S. distribution deal for PROIBS. Management outlined a FY27 roadmap with quarterly milestones.StocktwitsIMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?Immuron shares surged over 60% after signing an exclusive U.S. distribution deal with Calmino for its Proibs digestive-health device. A study of 1,003 users showed 94% found it helpful, and the company targets a $4.16 billion market. The stock is on track for its biggest single-day gain since March 2024.MarketScreenerTop Premarket GainersImmuron Limited, an Australia-based biopharmaceutical company, develops orally delivered polyclonal antibodies for infectious diseases. Its flagship products are Travelan, a passive immunotherapy for traveler's diarrhea, and Protectyn, an immune supplement. The company's clinical programs include Travelan and IMM-529.Quiver QuantitativeImmuron Limited Signs Exclusive U.S. Distribution Agreement for PROIBS with Calmino Group AB | IMRN Stock NewsImmuron Limited announced an exclusive U.S. distribution agreement for PROIBS, a digestive health supplement from Calmino group AB. The U.S. gut health supplement market is valued at $4.16 billion, and PROIBS showed 94% user satisfaction in a study of 1,003 participants.